Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma

Journal of Clinical Oncology

Volumn 31, Issue 17, 2013, Pages 2152-2159

  Dudley, Mark E ^a   Gross, Colin A ^a   Somerville, Robert P T ^a   Hong, Young ^a   Schaub, Nicholas P ^a   Rosati, Shannon F ^a   White, Donald E ^a   Nathan, Debbie ^a   Restifo, Nicholas P ^a   Steinberg, Seth M ^a   Wunderlich, John R ^a   Kammula, Udai S ^a   Sherry, Richard M ^a   Yang, James C ^a   Phan, Giao Q ^a   Hughes, Marybeth S ^a   Laurencot, Carolyn M ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2;

ADOLESCENT; ADOPTIVE CELL THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CATHETER INFECTION; CELL THERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MEGADOSE; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOXIA; MALE; METASTATIC MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; SEPSIS; SOMNOLENCE; SURVIVAL; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UPPER RESPIRATORY TRACT INFECTION; ADOPTIVE IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MELANOMA; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; TRANSPLANTATION; TUMOR CELL CULTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84887991307     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.46.6441     Document Type: Article

References (29)

1. Rosenberg SA: Cell transfer immunotherapy for metastatic solid cancer: What clinicians need to know. Nat Rev Clin Oncol 8:577-585, 2011
2. Rosenberg SA, Yang JC, Sherry RM, et al: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17:4550-4557, 2011
3. Goff SL, Smith FO, Klapper JA, et al: Tumor infiltrating lymphocyte therapy for metastatic melanoma: Analysis of tumors resected for TIL. J Immunother 33:840-847, 2010
4. Tran KQ, Zhou J, Durflinger KH, et al: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 31:742-751, 2008
5. Itzhaki O, Hovav E, Ziporen Y, et al: Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother 34:212-220, 2011
6. Somerville RP, Dudley ME: Bioreactors get personal. Oncoimmunology 1:1435-1437, 2012
7. Ullenhag GJ, Sadeghi AM, Carlsson B, et al: Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy. Cancer Immunol Immunother 61: 725-732, 2012
8. Vera JF, Brenner LJ, Gerdemann U, et al: Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 33:305-315, 2010
9. Jin J, Sabatino M, Somerville R, et al: Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. J Immunother 35:283-292, 2012
10. Somerville RP, Devillier L, Parkhurst MR, et al: Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE(R) bioreactor. J Transl Med 10:69, 2012
11. Friedman KM, Prieto PA, Devillier LE, et al: Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother 35:400-408, 2012
12. Hunder NN, Wallen H, Cao J, et al: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008
13. Wang HY, Lee DA, Peng G, et al: Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 20:107-118, 2004
14. + regulatory T cells. J Immunol 174:2661-2670, 2005
15. Yao X, Ahmadzadeh M, Lu YC, et al: Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119: 5688-5696, 2012
16. Dudley ME, Gross CA, Langhan MM, et al: CD8 enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res 16:6122-6131 2010
17. Pilon-Thomas S, Kuhn L, Ellwanger S, et al: Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J Immunother 35:615-620, 2012
18. Dudley ME, Wunderlich JR, Yang JC, et al: Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357, 2005
19. + cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. J Immunother 33:547-556, 2010
20. Dudley ME, Wunderlich JR, Shelton TE, et al: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332-342, 2003
21. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 128:189-201, 1990
22. Dudley ME, Yang JC, Sherry R, et al: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26:5233-5239, 2008
23. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 86:1159-1166, 1994
24. Kawakami Y, Eliyahu S, Jennings C, et al: Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968, 1995
25. Smith FO, Klapper JA, Wunderlich JR, et al: Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma. J Immunother 32:870-874, 2009
26. Ribas A, Hersey P, Middleton MR, et al: New challenges in end points for drug development in advanced melanoma. Clin Cancer Res 18:336-341, 2012
27. Brenner MK: Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther 19:818-821, 2012
28. Donia M, Junker N, Ellebaek E, et al: Characterization and comparison of “standard” and “young” tumor infiltrating lymphocytes for adoptive cell therapy at a Danish Translational Research Institution. Scand J Immunol 75:157-167, 2012
29. Radvanyi LG, Bernatchez C, Zhang M, et al: Specific lymphocyte subsets predict response to adoptive cell therapy by using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18:6758-6770, 2012